Welcome to CM Online Store!
Antibody Drug Conjugate Kits!
AqT bioconjugates coming soon!
Shop by Brand
ADC Kits
CellMosaic ADC PerKits®
| Download Documents | |
| ADC FLYER | |
| APPLICATION NOTE |
Historically, antibody-drug conjugation was performed solely by drug developers, occasionally in collaboration with contract research organization (CRO). The cost of these services can be prohibitive for academia institutions and small biotech companies. During the screening stages, researchers often need to prepare various ADCs with different antibodies and drugs.
CellMosaic's ADC PerKits® are designed to prepare antibody-drug conjugates through surface amines or reduced thiols. Some kits are applicable for general payloads with specific functional groups, while others provide selected standard linker molecules conjugated to a chosen payload. Each kit includes the necessary reagents and protocols for attaching the selected payload to the customer’s antibody and purifying the final ADC. Customers only need to supply their antibody and standard lab equipment.
A typical CellMosaic personalized ADC kit yields approximately 2-3 mg of final ADC in buffer, with an average Drug-to-Antibody Ratio (DAR) of 2-4. Purity levels are typically >90%, with less than 5% unreacted payload remaining. Individual results may vary depending on the specific antibody system you are using and the hydrophobicity of your payload. The kit instructions are comprehensive and easy to follow, and the procedure can typically be completed within 4 to 6 hours, requiring less than 1 hour of hands-on time.
As of August 2024, customers from over 112 organizations worldwide have used CellMosaic's ADC kits.
See the publications using CellMosaic's ADC PerKits® below.
Other products on the market for antibody screening may use a general secondary antibody or a general antibody affinity coupling (such as protein-A) to provide indirect conjugation. However, these indirect conjugation approaches can significantly affect the hydrodynamic size and physiological behaviors of ADCs (e.g., altering cleavage and degradation mechanisms). As a result, these products do not provide a fully representative approach for evaluating your novel ADC in screening or proof-of-concept (POC) studies.
PerKit® ADC Selection Guide
Product# |
Drug |
Mechanism of Action |
Protein |
Labeling Chemistry |
Linkage |
Scale of Reaction (Standard Kit) |
| CM11431 | Deruxtecan | Topoisomerase I Inhibitor | IgG Ab | Reduced thiol | Releasable (GGFG) | 1-3 mg |
| CM11434 | Deruxtecan (HL) | Topoisomerase I Inhibitor | IgG Ab | Reduced thiol | Releasable (GGFG) | 1-3 mg |
| CM11435 | Exatecan | Topoisomerase I Inhibitor | Ab or Protein | Surface amine | Stable | 6.67-20 nmol |
| CM11436 | Exatecan | Topoisomerase I Inhibitor | Ab or Protein | Surface amine | Releasable (VC-PAB) | 6.67-20 nmol |
| CM11408 | SN38 | Topoisomerase I Inhibitor | IgG Ab | Surface amine | Releasable (ester) | 1-3 mg |
| CM11438 | SN38 | Topoisomerase I Inhibitor | Ab or Protein | Surface amine | Releasable (VC-PAB) | 6.67-20 nmol |
| CM11410 | DM1 | Tubulin Polymerization Inhibitor | IgG Ab | Surface amine | Stable | 0.1 mg, 1-3 mg |
| CM11419 | DM1 | Tubulin Polymerization Inhibitor | F(ab')2 | Surface amine | Stable | 0.73-2.2 mg |
| CM11409 | MMAE | Tubulin Polymerization Inhibitor | IgG Ab | Reduced thiol | Releasable (VC-PAB) | 0.1 mg, 1-3 mg |
| CM11416 | MMAE | Tubulin Polymerization Inhibitor | F(ab')2 | Reduced thiol | Releasable (VC-PAB) | 0.73-2.2 mg |
| CM11422 | MMAF | Tubulin Polymerization Inhibitor | IgG Ab | Reduced thiol | Stable | 1-3 mg |
| CM11425 | MMAF | Tubulin Polymerization Inhibitor | IgG Ab | Reduced thiol | Releasable (VC-PAB) | 1-3 mg |
| CM11407 | Methotrexate | Dihydrofolate Reductase (DHFR) Inhibitor | IgG Ab | Surface amine | Stable | 1-3 mg |
| CM11406 | Doxorubicin | DNA Intercalation, Topoisomerase II inhibitor | IgG Ab | Surface amine | Stable | 1-3 mg |
| CM11433 | UM171 | Proteasomal Degradation | IgG Ab | Surface amine | Stable | 1-3 mg |
| CM11439 | PBD Dimer | DNA Binding | Ab or Protein | Surface amine | Releasable (VA) | 6.67-20 nmol |
| CM11429 | No drug (VC-PAB linker only) | No drug (VC-PAB linker only) | IgG Ab | Reduced thiol | Releasable (VC-PAB) | 1-3 mg |
| CM51403 | Acid | N/A (Customer Supplied) | IgG Ab | Surface amine | Stable | 1-3 mg |
AqT® ADC Drug Development & ManufacturingWhen conventional linkers fail to enable drug conjugation or when the therapeutic efficacy of an ADC is hindered by payload limitations, CellMosaic has developed a breakthrough solution: AqueaTether® (AqT®) linkers. These super-hydrophilic, high-loading linkers are designed to enhance payload solubility, stability, and conjugation efficiency, overcoming key challenges in ADC development. To explore the full potential of AqT® technologies, click here. Interested in integrating this cutting-edge platform into your novel ADC development? Learn more here. |
Selected Citations from Customers who Use ADC Prepared from CellMosaic's ADC Kits
1. Lofgren, Kristopher A.; Sreekumar, Sreeja; Jenkins, Charles E., Jr.; Ernzen, Kyle J.; Kenny, Paraic A. "Anti-tumor efficacy of an MMAE-conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer." Antibody Therapeutics 2021, 4 (4), 252-261.
2. Neetha Parameswaran, Liping Luo, Lingjun Zhang, Joel Chen, Frank P. DiFilippo, Charlie Androjna, David A. Fox, Sarah L. Ondrejka, Eric D. Hsi, Deepa Jagadeesh, Daniel J. Lindner & Feng Lin. "CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma" Leukemia 2023, 37, 2050-2057.
3. Micalizzi, Douglas S.; Che, Dante: Nicholson, Benjamin T.; Edd, Jon F.; Desai, Niyati; Lang, Evan R.; Toner, Mehmet; Maheswaran, Shyamala; Ting, David T.; Haber, Daniel A. "Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody." PNAS 2022, 43 (119), e2209563119.
3. Guido J J Kierkels, Eline van Diest, Patricia Hernández-López, Wouter Scheper, Anja C M de Bruin, Elselien Frijlink, Tineke Aarts-Riemens, Sanne F J van Dooremalen, Dennis X Beringer, Rimke Oostvogels, Lovro Kramer, Trudy Straetemans, Wolfgang Uckert, Zsolt Sebestyén, Jürgen Kuball. "Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells" Mol Ther Methods Clin Dev. 2021, 22, 388-400.
4. Zehua Sun, Xiaojie Chu, Cynthia Adams, Tatiana V Ilina, Michel Guerrero, Guowu Lin, Chuan Chen, Dontcho Jelev, Rieko Ishima, Wei Li, John W Mellors, Guillermo Calero, Dimiter S Dimitrov. "Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate" Mol Ther Oncolytics 2023 31:100726. doi: 10.1016/j.omto.2023.09.002. eCollection 2023 Dec 19.